These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21827675)

  • 41. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
    Zeng W; Su M; Anderson KS; Sasada T
    Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CTLA-4 blockade boosts the expansion of tumor-reactive CD8
    Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö
    Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
    Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
    Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD4
    Lu J; Huang C; He R; Xie R; Li Y; Guo X; Zhang Q; Xu Q
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9007-9016. PubMed ID: 37165118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.
    Noguchi K; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Tani M; Mizobata S; Hotta T; Arii K; Tamai M
    Anticancer Res; 1995; 15(2):255-8. PubMed ID: 7762991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4.
    Tso CL; Duckett T; deKernion JB; Belldegrun AS
    J Immunother (1991); 1992 Aug; 12(2):82-9. PubMed ID: 1504057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
    Brimnes MK; Gang AO; Donia M; Thor Straten P; Svane IM; Hadrup SR
    Cancer Immunol Immunother; 2012 Aug; 61(8):1221-31. PubMed ID: 22237888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 53. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer.
    Friedl J; Stift A; Paolini P; Roth E; Steger GG; Mader R; Jakesz R; Gnant MF
    Cancer Biother Radiopharm; 2000 Oct; 15(5):477-86. PubMed ID: 11155819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
    Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
    Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PGE
    Morotti M; Grimm AJ; Hope HC; Arnaud M; Desbuisson M; Rayroux N; Barras D; Masid M; Murgues B; Chap BS; Ongaro M; Rota IA; Ronet C; Minasyan A; Chiffelle J; Lacher SB; Bobisse S; Murgues C; Ghisoni E; Ouchen K; Bou Mjahed R; Benedetti F; Abdellaoui N; Turrini R; Gannon PO; Zaman K; Mathevet P; Lelievre L; Crespo I; Conrad M; Verdeil G; Kandalaft LE; Dagher J; Corria-Osorio J; Doucey MA; Ho PC; Harari A; Vannini N; Böttcher JP; Dangaj Laniti D; Coukos G
    Nature; 2024 May; 629(8011):426-434. PubMed ID: 38658764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.